Skip to main content
Golimumab is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate (MTX), active psoriatic arthritis, and active ankylosing spondylitis with or without methotrexate or other non-biologic disease-modifying antirheumatic drug (DMARD).

Pharmacology Update: Golimumab Injection (Simponi™)

Golimumab is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate (MTX), active psoriatic arthritis, and active ankylosing spondylitis with or without methotrexate or other non-biologic disease-modifying antirheumatic drug (DMARD).